Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

Layla-Grace is a happy, determined and chatty little girl who loves music and playing outside. The 18-month-old has been ...

AstraZeneca unveiled promising new data for two of its cancer drugs — Enhertu and Tagrisso — giving the pharma giant the ...

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the ...

Little Johnstons star Liz Johnston revealed her reaction to learning that her daughter, Leighton Drew, is a normal-sized baby ...

Before Liz announced that her daughter would be average height, her parents Trent and Amber Johnston had their fingers not-so ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.